deltatrials
Completed PHASE3 NCT00039013

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Alone

Sponsor: AstraZeneca

Conditions Diabetes Mellitus, Type 2
Interventions AC2993 Placebo
Updated 7 times since 2017 Last updated: Feb 23, 2015 Started: Mar 31, 2002 Primary completion: Jun 30, 2003 Completion: Jun 30, 2003

A PHASE3 clinical study on Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Anaheim, United States, Anniston, United States, Austin, United States, Bakersfield, United States, Baltimore, United States, Belvidere, United States, Birmingham, United States, Bloomfield Hills, United States, Brooklyn, United States and 90 more location s